Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database

On behalf of the SEARCH Database Study Group

Research output: Contribution to journalArticle

Abstract

Objectives: To examine the association between body mass index (BMI) and aggressive biochemical recurrence (BCR) using the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Material and Methods: We identified 4123 men with complete data treated by radical prostatectomy between 1988 and 2015. We tested the association between BMI and BCR using Cox models, and among men with BCR, prostate-specific antigen doubling time (PSADT) was compared across BMI categories using linear regression. Models were adjusted for age, race, prostate-specific antigen, biopsy Gleason score, clinical stage, year and surgical centre. Results: Overall, 922 men (22%) were of normal weight (BMI <25 kg/m2), 1863 (45%) were overweight (BMI 25–29.9 kg/m2), 968 (24%) were obese (BMI 30–34.9 kg/m2), and 370 (9%) were moderately or severely obese (BMI ≥35 kg/m2). After adjustment for multiple clinical characteristics, higher BMI was significantly associated with higher risk of BCR (P = 0.008). Among men with BCR, men in the four BMI categories had similar multivariable-adjusted PSADT values (increasing BMI categories: 20.9 vs 21.3 vs 21.0 vs 14.9 months; P = 0.48). Conclusion: While we confirmed that higher BMI was associated with BCR, we found no link between BMI and PSADT at the time of recurrence. Our data suggest obese men do not have more aggressive recurrences. Future studies are needed to test whether obesity predicts response to salvage therapies.

Original languageEnglish (US)
JournalBJU International
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cancer Care Facilities
Prostate-Specific Antigen
Prostatectomy
Body Mass Index
Obesity
Databases
Recurrence
Salvage Therapy
Neoplasm Grading
Proportional Hazards Models
Linear Models

Keywords

  • #PCSM
  • #ProstateCancer
  • #uroonc
  • obesity
  • prostate cancer
  • PSA doubling time
  • PSA recurrence
  • radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy : results from the SEARCH database. / On behalf of the SEARCH Database Study Group.

In: BJU International, 01.01.2018.

Research output: Contribution to journalArticle

@article{ca320735016349e2afc62da625a239ee,
title = "Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database",
abstract = "Objectives: To examine the association between body mass index (BMI) and aggressive biochemical recurrence (BCR) using the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Material and Methods: We identified 4123 men with complete data treated by radical prostatectomy between 1988 and 2015. We tested the association between BMI and BCR using Cox models, and among men with BCR, prostate-specific antigen doubling time (PSADT) was compared across BMI categories using linear regression. Models were adjusted for age, race, prostate-specific antigen, biopsy Gleason score, clinical stage, year and surgical centre. Results: Overall, 922 men (22{\%}) were of normal weight (BMI <25 kg/m2), 1863 (45{\%}) were overweight (BMI 25–29.9 kg/m2), 968 (24{\%}) were obese (BMI 30–34.9 kg/m2), and 370 (9{\%}) were moderately or severely obese (BMI ≥35 kg/m2). After adjustment for multiple clinical characteristics, higher BMI was significantly associated with higher risk of BCR (P = 0.008). Among men with BCR, men in the four BMI categories had similar multivariable-adjusted PSADT values (increasing BMI categories: 20.9 vs 21.3 vs 21.0 vs 14.9 months; P = 0.48). Conclusion: While we confirmed that higher BMI was associated with BCR, we found no link between BMI and PSADT at the time of recurrence. Our data suggest obese men do not have more aggressive recurrences. Future studies are needed to test whether obesity predicts response to salvage therapies.",
keywords = "#PCSM, #ProstateCancer, #uroonc, obesity, prostate cancer, PSA doubling time, PSA recurrence, radical prostatectomy",
author = "{On behalf of the SEARCH Database Study Group} and Freedland, {Stephen J.} and Branche, {Brandee L.} and Howard, {Lauren E.} and Hamilton, {Robert J.} and Aronson, {William J.} and Terris, {Martha K.} and Cooperberg, {Matthew R.} and Christopher Amling and Kane, {Christopher J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/bju.14594",
language = "English (US)",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy

T2 - results from the SEARCH database

AU - On behalf of the SEARCH Database Study Group

AU - Freedland, Stephen J.

AU - Branche, Brandee L.

AU - Howard, Lauren E.

AU - Hamilton, Robert J.

AU - Aronson, William J.

AU - Terris, Martha K.

AU - Cooperberg, Matthew R.

AU - Amling, Christopher

AU - Kane, Christopher J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: To examine the association between body mass index (BMI) and aggressive biochemical recurrence (BCR) using the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Material and Methods: We identified 4123 men with complete data treated by radical prostatectomy between 1988 and 2015. We tested the association between BMI and BCR using Cox models, and among men with BCR, prostate-specific antigen doubling time (PSADT) was compared across BMI categories using linear regression. Models were adjusted for age, race, prostate-specific antigen, biopsy Gleason score, clinical stage, year and surgical centre. Results: Overall, 922 men (22%) were of normal weight (BMI <25 kg/m2), 1863 (45%) were overweight (BMI 25–29.9 kg/m2), 968 (24%) were obese (BMI 30–34.9 kg/m2), and 370 (9%) were moderately or severely obese (BMI ≥35 kg/m2). After adjustment for multiple clinical characteristics, higher BMI was significantly associated with higher risk of BCR (P = 0.008). Among men with BCR, men in the four BMI categories had similar multivariable-adjusted PSADT values (increasing BMI categories: 20.9 vs 21.3 vs 21.0 vs 14.9 months; P = 0.48). Conclusion: While we confirmed that higher BMI was associated with BCR, we found no link between BMI and PSADT at the time of recurrence. Our data suggest obese men do not have more aggressive recurrences. Future studies are needed to test whether obesity predicts response to salvage therapies.

AB - Objectives: To examine the association between body mass index (BMI) and aggressive biochemical recurrence (BCR) using the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Material and Methods: We identified 4123 men with complete data treated by radical prostatectomy between 1988 and 2015. We tested the association between BMI and BCR using Cox models, and among men with BCR, prostate-specific antigen doubling time (PSADT) was compared across BMI categories using linear regression. Models were adjusted for age, race, prostate-specific antigen, biopsy Gleason score, clinical stage, year and surgical centre. Results: Overall, 922 men (22%) were of normal weight (BMI <25 kg/m2), 1863 (45%) were overweight (BMI 25–29.9 kg/m2), 968 (24%) were obese (BMI 30–34.9 kg/m2), and 370 (9%) were moderately or severely obese (BMI ≥35 kg/m2). After adjustment for multiple clinical characteristics, higher BMI was significantly associated with higher risk of BCR (P = 0.008). Among men with BCR, men in the four BMI categories had similar multivariable-adjusted PSADT values (increasing BMI categories: 20.9 vs 21.3 vs 21.0 vs 14.9 months; P = 0.48). Conclusion: While we confirmed that higher BMI was associated with BCR, we found no link between BMI and PSADT at the time of recurrence. Our data suggest obese men do not have more aggressive recurrences. Future studies are needed to test whether obesity predicts response to salvage therapies.

KW - #PCSM

KW - #ProstateCancer

KW - #uroonc

KW - obesity

KW - prostate cancer

KW - PSA doubling time

KW - PSA recurrence

KW - radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=85056635924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056635924&partnerID=8YFLogxK

U2 - 10.1111/bju.14594

DO - 10.1111/bju.14594

M3 - Article

C2 - 30347135

AN - SCOPUS:85056635924

JO - BJU International

JF - BJU International

SN - 1464-4096

ER -